Discovery of first-in-class DOT1L inhibitors against the R231Q gain-of-function mutation in the catalytic domain with therapeutic potential of lung cancer
2024 · Acta Pharmaceutica Sinica B · 3 citations
https://doi.org/10.1016/j.apsb.2024.03.018
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
9
Papers
74
Citations
4
h-index
2
i10-index
Zehui Tan is an academic researcher from Shenyang Pharmaceutical University. The author has contributed to research in topics: Epigenetics and DNA Methylation & Synthesis and biological activity & Cancer, Hypoxia, and Metabolism. The author has an h-index of 4, co-authored 8 publications.
Click to start Chat